NCT02220803View on ClinicalTrials.gov

A Short Term Open, Randomized Cross-over Trial Exploring the Effect of Carbonic Anhydrase Inhibition by Acetazolamide on Sleep Apnea Associated Hypertension and Vascular Dysfunction

PHASE2CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

August 31, 2016

Study Completion Date

August 31, 2016

Conditions
Obstructive Sleep ApneaSleep-Disordered BreathingBlood PressureHypertension
Interventions
DRUG

Acetazolamide

Acetazolamide, 250mg tablets, will be administrated as multiple doses. Dosing of acetazolamide will be up-titrated during 3 days according to manufacturer instruction and titration scheme of the study. Maximum daily dosage is 750 mg (equivalent of 3 tablets/daily). Evening medication should be taken 2 hours before bedtime. The total length of Acetazolamide treatment will be 4 weeks (2x2) including 3 days of titration phase of the drug.

DEVICE

nasal Continuous Positive Airway Pressure (nCPAP)

Trial Locations (1)

40530

Center for Sleep and Vigilance disorders, Gothenburg

All Listed Sponsors
lead

Göteborg University

OTHER

NCT02220803 - A Short Term Open, Randomized Cross-over Trial Exploring the Effect of Carbonic Anhydrase Inhibition by Acetazolamide on Sleep Apnea Associated Hypertension and Vascular Dysfunction | Biotech Hunter | Biotech Hunter